Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month …
HM Kantarjian, A Hochhaus, G Saglio… - The lancet …, 2011 - thelancet.com
Background Nilotinib has shown greater efficacy than imatinib in patients with newly
diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic …
diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic …
Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With …
Purpose We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in
chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …
chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …
Considerations for designing preclinical cancer immune nanomedicine studies
Immunotherapy is known to be clinically beneficial for cancer patients and in many cases
represents the new standard of care. Because of this success, the interest in integrating …
represents the new standard of care. Because of this success, the interest in integrating …
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
AS Corbin, A Agarwal, M Loriaux… - The Journal of …, 2011 - Am Soc Clin Investig
Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic
myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most …
myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most …
Standardized definitions of molecular response in chronic myeloid leukemia
Abstract The International Randomized Study of Interferon and STI571 (IRIS) demonstrated
long-term cytogenetic responses in patients with chronic-phase chronic myeloid leukemia …
long-term cytogenetic responses in patients with chronic-phase chronic myeloid leukemia …
Granulocyte–macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
CHM Jamieson, LE Ailles, SJ Dylla… - … England Journal of …, 2004 - Mass Medical Soc
Background The progression of chronic myelogenous leukemia (CML) to blast crisis is
supported by self-renewing leukemic stem cells. In normal mouse hematopoietic stem cells …
supported by self-renewing leukemic stem cells. In normal mouse hematopoietic stem cells …
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR …
The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase …
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase …
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
M Baccarani, G Saglio, J Goldman, A Hochhaus… - Blood, 2006 - ashpublications.org
The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger, E Buchdunger, BJ Druker - Blood, 2005 - ashpublications.org
Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical
studies were promising but the results of clinical trials by far exceeded expectations …
studies were promising but the results of clinical trials by far exceeded expectations …
Chronic myeloid leukemia—advances in biology and new approaches to treatment
JM Goldman, JV Melo - New England Journal of Medicine, 2003 - Mass Medical Soc
An extraordinary series of discoveries about chronic myeloid leukemia (CML) has made this
disease a model of the way in which bench and bedside research can unite and culminate …
disease a model of the way in which bench and bedside research can unite and culminate …